| ［1］ |
Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis⁃like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis［J］. Clin Rheumatol, 2009, 28（8）: 979⁃984. DOI: 10.1007/s10067⁃009⁃1152⁃9.
|
| ［2］ |
Robinson ES, Feng R, Okawa J, et al. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life［J］. Br J Dermatol, 2015, 172（1）: 169⁃174. DOI: 10.1111/bjd.13167.
|
| ［3］ |
沈敏, 龚瑜林, 曾小峰, 等. 以间质性肺疾病起病的皮肌炎临床特点分析［J］. 中华医学杂志, 2014, 94（43）: 3402⁃3406. DOI: 10.3760/cma.j.issn.0376⁃2491.2014.43.011.
|
| ［4］ |
Ortigosa LC, Reis VM. Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas （HCFMUSP）, São Paulo, Brazil［J］. An Bras Dermatol, 2014, 89（5）: 719⁃727.
|
| ［5］ |
Finsterer J, Wakil S. Abnormalities of skin and cutaneous appendages in neuromuscular disorders［J］. Pediatr Neurol, 2015, 53（4）: 301⁃308. DOI: 10.1016/j.pediatrneurol.2015.03.005.
|
| ［6］ |
Vuong V, Duong TA, Aouizerate J, et al. Dermatomyositis: factors predicting relapse［J］. J Eur Acad Dermatol Venereol, 2016, 30（5）:813⁃818. DOI: 10.1111/jdv.13516.
|
| ［7］ |
Yassaee M, Fiorentino D, Okawa J, et al. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument［J］. Br J Dermatol, 2010, 162（3）: 669⁃673. DOI: 10.1111/j.1365⁃2133.2009.09521.x.
|
| ［8］ |
Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing （MMT）, health assessment questionnaire （HAQ）/childhood health assessment questionnaire （C⁃HAQ）, childhood myositis assessment scale （CMAS）, myositis disease activity assessment tool （MDAAT）, disease activity score （DAS）, short form 36 （SF⁃36）, child health questionnaire （CHQ）, physician global damage, myositis damage index （MDI）, quantitative muscle testing （QMT）, myositis functional index⁃2 （FI⁃2）, myositis activities profile （MAP）, inclusion body myositis functional rating scale （IBMFRS）, cutaneous dermatomyositis⁃disease area and severity index （CDASI）, cutaneous assessment tool （CAT）, dermatomyositisskin severity index （DSSI）, skindex, and dermatology life quality index （DLQI）［J］. Arthritis Care Res （Hoboken）, 2011, 63 Suppl 11: S118⁃157. DOI: 10.1002/acr.20532.
|
| ［9］ |
Goreshi R, Okawa J, Rose M, et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT⁃BM［J］. J Invest Dermatol, 2012, 132（4）: 1117⁃1124. DOI: 10.1038/jid.2011.440.
|
| ［10］ |
Klein RQ, Bangert CA, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis［J］. Br J Dermatol, 2008, 159（4）: 887⁃894. DOI: 10.1111/j.1365⁃2133.2008.08711.x.
|
| ［11］ |
Iaccarino L, Ghirardello A, Bettio S, et al. The clinical features, diagnosis and classification of dermatomyositis［J］. J Autoimmun, 2014, 48⁃49:122⁃127. DOI: 10.1016/j.jaut.2013.11.005.
|
| ［12］ |
Carroll CL, Lang W, Snively B, et al. Development and validation of the Dermatomyositis Skin Severity Index［J］. Br J Dermatol, 2008, 158（2）: 345⁃350. DOI: 10.1111/j.1365⁃2133.2007.08342.x.
|
| ［13］ |
Dalakas MC. Inflammatory muscle diseases［J］. N Engl J Med, 2015, 372（18）: 1734⁃1747. DOI: 10.1056/NEJMra1402225.
|
| ［14］ |
Huber AM, Dugan EM, Lachenbruch PA, et al. The cutaneous assessment tool: development and reliability in juvenile idiopathic inflammatory myopathy［J］. Rheumatology （Oxford）, 2007, 46（10）: 1606⁃1611. DOI: 10.1093/rheumatology/kem179.
|
| ［15］ |
Campanilho⁃Marques R, Almeida B, Deakin C, et al. Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with Juvenile Dermatomyositis［J/OL］. Arthritis Care Res（Hoboken）, 2016. http://onlinelibrary.wiley.com/doi/10.1002/acr.22867/epdf. ［published online ahead of print Feb 16, 2016］. DOI: 10.1002/acr.22867.
|
| ［16］ |
Huber AM, Lachenbruch PA, Dugan EM, et al. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermato⁃myositis: results using abbreviated formats［J］. Arthritis Rheumatol, 2008, 59（3）: 352⁃356. DOI: 10.1002/art.23313.
|
| ［17］ |
Huber AM, Dugan EM, Lachenbruch PA, et al. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis［J］. Arthritis Rheumatol, 2008,59（2）: 214⁃221. DOI: 10.1002/art.23340.
|
| ［18］ |
Robinson, AB, Reed, AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis［J］. Nat Rev Rheumatol, 2011, 7（11）: 664⁃675. DOI: 10.1038/nrrheum.2011. 139.
|
| ［19］ |
Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review［J/OL］. Clin Rev Allergy Immunol, 2015.http://link.springer.com/article/10.10072Fs12016⁃015⁃8511⁃x.［published online ahead of print Oct 01,2015］. DOI: 10.1007/s12016⁃015⁃8511⁃x.
|
| ［20］ |
Almeida B,Campanilho⁃Marques R, Arnold R, et al. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated［J］. Arthritis Rheumatol, 2015, 67（9）: 2495⁃2502. DOI: 10.1002/art.39200.
|
